BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7796648)

  • 1. [Overexpression of p53 in transitional cell carcinoma of the ovary].
    Shen K; Lang J; Guo L
    Zhonghua Fu Chan Ke Za Zhi; 1995 Mar; 30(3):153-6. PubMed ID: 7796648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Overexpression of C-erbB3 in transitional cell carcinoma of the ovary].
    Shen K; Lang J; Guo L
    Zhonghua Fu Chan Ke Za Zhi; 1995 Nov; 30(11):658-61. PubMed ID: 8745489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
    Cuatrecasas M; Catasus L; Palacios J; Prat J
    Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relation between p53 overexpression and lymph node metastases in clinical stage t2 and t3a transitional cell bladder carcinoma.
    Uygur MC; Yaman I; Kutluay L; Altuğ U; Erol D
    J Exp Clin Cancer Res; 1999 Sep; 18(3):391-5. PubMed ID: 10606186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder.
    Furihata M; Inoue K; Ohtsuki Y; Hashimoto H; Terao N; Fujita Y
    Cancer Res; 1993 Oct; 53(20):4823-7. PubMed ID: 8402668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of bcl-2 and bcl-X in bladder cancer.
    Kirsh EJ; Baunoch DA; Stadler WM
    J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
    Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
    Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 overexpression and human papillomavirus infection in transitional cell carcinoma of the urinary bladder: correlation with histological parameters.
    Tenti P; Zappatore R; Romagnoli S; Civardi E; Giunta P; Scelsi R; Stella G; Carnevali L
    J Pathol; 1996 Jan; 178(1):65-70. PubMed ID: 8778319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma.
    Tiguert R; Bianco FJ; Oskanian P; Li Y; Grignon DJ; Wood DP; Pontes JE; Sarkar FH
    J Urol; 2001 Dec; 166(6):2155-60. PubMed ID: 11696726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
    Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas.
    Bernardini S; Adessi GL; Billerey C; Chezy E; Carbillet JP; Bittard H
    J Urol; 1999 Oct; 162(4):1496-501. PubMed ID: 10492244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 mutation is infrequent in clear cell carcinoma of the ovary.
    Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
    Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P53 expression in small cell carcinoma of the urinary bladder: biological and prognostic implications.
    Wang X; Jones TD; Maclennan GT; Yang XJ; Lopez-Beltran A; Eble JN; Koch MO; Lin H; Baldridge LA; Tretiakova M; Cheng L
    Anticancer Res; 2005; 25(3B):2001-4. PubMed ID: 16158936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
    Gumus E; Erdamar S; Demirel G; Horasanli K; Kendirci M; Miroglu C
    Int J Urol; 2004 Dec; 11(12):1070-7. PubMed ID: 15663677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
    Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG
    Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients.
    Goan YG; Hsu HK; Chang HC; Chou YP; Chiang KH; Cheng JT
    Ann Thorac Surg; 2005 Sep; 80(3):1007-16. PubMed ID: 16122475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder.
    Fleshner N; Kapusta L; Ezer D; Herschorn S; Klotz L
    J Urol; 2000 Oct; 164(4):1177-82. PubMed ID: 10992361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of mutant P53 gene protein product in human bladder carcinoma].
    Ye DW
    Zhonghua Wai Ke Za Zhi; 1993 Aug; 31(8):484-6. PubMed ID: 8112175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.